Show Summary Details
Page of

Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration 

Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
Chapter:
Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
Author(s):

Michael Maksimowski

, and Zheala Qayyum

DOI:
10.1093/med/9780190625085.003.0026
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 September 2020

This chapter provides a summary of a landmark study on major depressive disorder. What are the drug–placebo differences among antidepressants when both published and unpublished data are analyzed? Does antidepressant efficacy depend on the severity of initial depression scores? Starting with these questions, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The main finding from this meta-analysis is that antidepressant-placebo differences are inconsequential for mildly-to-moderately depressed patients and minimal for severely depressed patients. The chapter briefly reviews other relevant studies and information, discusses implications, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.